P1/2, N=120, Not yet recruiting, City of Hope Medical Center | Initiation date: Dec 2026 --> Dec 2025

We report the first documented case of myocarditis linked to the novel bifunctional PD-1/CTLA-4 combination, Iparomlimab and Tuvonralimab. This case highlights that structural drug optimizations do not preclude severe cardiotoxicity. In resource-limited settings lacking advanced imaging, serial high-sensitivity troponin monitoring served as the cornerstone for early detection and guiding management. This experience confirms that favorable outcomes are achievable through vigilant biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics.

Ten cases (average age 54.4 years) were immunosuppressed, with a range of aetiologies from lymphoma (n = 3) to azathioprine for inflammatory bowel disease (n = 2)...Because 84% of melanomas were detected at follow-up, and by Breslow thickness they were uniformly thin, this supports the effectiveness of the follow-up approach here. This evaluation of individuals with numerous melanocytic naevi supports this approach as an effective use of resources.

P=N/A, N=20, Recruiting, University of Chicago | Trial primary completion date: Sep 2025 --> Jun 2030

The patient was treated with prednisolone and mycophenolate mofetil, with close outpatient follow-up...This case highlights an atypical presentation of systemic scleroderma with band acro-osteolysis and dactylitis, emphasizing the importance of recognizing uncommon manifestations for early diagnosis and intervention. The multifactorial pathogenesis, involving vascular dysfunction and inflammation, underscores the need for personalized management to prevent complications.

P2, N=10, Recruiting, University of Chicago | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital

Immunosuppression with calcineurin inhibitor (CNI) plus azathioprine (AZA) was independently associated with increased skin cancer risk (odds ratio [OR] 9.41, p = 0.044), especially for SCC (OR 6.6, p = 0.027)...Skin cancer is a relevant long-term complication after HTx, particularly SCC in patients receiving AZA. Our findings support limiting AZA use and reinforce the importance of structured dermatologic surveillance and early mammalian target of rapamycin conversion strategies to improve long-term outcomes.

The current guideline describes the gene-drug interactions for TPMT, NUDT15 and thiopurines (azathioprine, 6-mercaptopurine and thioguanine). For TPMT or NUDT15 IM treated for leukaemia, starting with the normal dose can be considered and then decrease the dose to the advised dose described above in case toxicities occur. For NUDT15 PM reduced starting dose is advised only if an alternative is not possible, due to a higher uncertainty in the calculated dose reduction for NUDT15 PM than for TPMT PM.DPWG classifies genotyping for TPMT and NUDT15 "essential" before thiopurine initiation.

P2, N=355, Completed, Abivax S.A. | Phase classification: P2b --> P2 | N=254 --> 355

P2, N=60, Recruiting, University of Florida | Not yet recruiting --> Recruiting

The niosomal formulation of MEF synergistically enhances CIS efficacy by promoting apoptosis, and suppressing angiogenesis in TNBC. These findings highlight NMEF as a promising chemosensitizer to overcome cisplatin resistance. Future studies should focus on in vivo validation and clinical translation.